Full Press Release Details
IDEAYA Biosciences Announces First Patient In for Phase 1 Clinical Trial Evaluating IDE397 and Trodelvy R Combination in MTAP Deletion Bladder Cancer.
IDYA
IDEAYA Biosciences Announces First Patient In for Phase 1 Clinical Trial Evaluating IDE397 and Trodelvy R Combination in MTAP Deletion Bladder Cancer
Key Takeaway: IDEAYA Biosciences Announces First Patient In for Phase 1 Clinical Trial Evaluating IDE397 and Trodelvy R Combination in MTAP Deletion Bladder Cancer
Price reaction · baseline $37 (2024-06-24 close) · hit after-hours · 1 other IDYA headline(s) in the window, move may be shared
day 0 close · peak
-2.4%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+47%
120-day peak, hindsight
Typical move
5.2%
average across 6 past catalysts
Cash runway
~42 mo
Minimal dilution risk
Lead asset
IDE892
Phase 1 · NSCLC Adenocarcinoma